Last reviewed · How we verify
Calcium channel blocker strategy
At a glance
| Generic name | Calcium channel blocker strategy |
|---|---|
| Also known as | diltiazem and verapamil |
| Sponsor | Boston University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication (NA)
- Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals (PHASE4)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION） (NA)
- China Antihypertensive Trial in Acute Ischemic Stroke II (PHASE3)
- Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa (NA)
- Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT) (PHASE4)
- Rapid Atrial Fibrillation Treatment Strategy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium channel blocker strategy CI brief — competitive landscape report
- Calcium channel blocker strategy updates RSS · CI watch RSS
- Boston University portfolio CI